Phase 2a Study of HPG1860 in Subjects With NASH
| 対象疾患 | NASH - Nonalcoholic Steatohepatitis |
|---|---|
| 相 | 第2相 |
| スポンサー | Hepagene (Shanghai) Co., Ltd. |
| ステータス | 完了 |
| 参加者数 | 89 名 |
| 介入（薬剤） | HPG1860 |
| 開始日 | 2021年11月22日 |
| 完了日 | 2023年2月28日 |
| 結果公開日 | 2026年5月28日 |
概要
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
Safety and Tolerability of Treatment
| Placebo | 12 Participants |
|---|---|
| HPG1860 3 mg | 13 Participants |
| HPG1860 5 mg | 13 Participants |
| HPG1860 8 mg | 18 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
- Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
- Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
- Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
- Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)